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Abstract
Objective: To study the prevalence and correlates of increased urinary albumin excretion (UAE)
in an Iranian type 2 diabetic population.
Methods: Over a one year period since October 2002, 400 consecutive type 2 diabetic patients
referred to an outpatient diabetes clinic, were enrolled in a cross sectional study. Subjects had no
history of renal impairment or overt proteinuria. Data concerning demographic characteristics and
cardiovascular risk factors were recorded and height, weight and blood pressure were measured.
Glucose, cholesterol, HDL-C, LDL-C, triglyceride, apoprotein B, lipoprotein a, creatinine, and
HbA1c were measured in fasting blood samples. Overnight twelve-hour UAE were assessed by
immunoturbidometry method. Regression analyses were employed to determine the correlates of
UAE.
Results: Out of 400 patients, 156 (40%) subjects had increased UAE (UAE ≥ 30 mg/24 hour). The
UAE was higher in males compared to females (145.5 vs. 72.1 mg/day; p < 0.05); however, the age
and HDL adjusted UAE levels were not significantly different between men and women (120.1 vs.
and 87.9 mg/day; p = 0.37). Increased UAE was correlated with decreasing HDL-C and a longer
duration of diabetes independent of other variables; increased UAE was correlated with HbA1c as
well. Age, systolic and diastolic blood pressure, total cholesterol, LDL-C, triglyceride, apoprotein
B, lipoprotein a, and GFR did not correlate with increased UAE.
Conclusion:  In this study, increased UAE was considerably frequent among type 2 diabetic
patients without any significant history of renal dysfunction. Albuminuria was found to be associated
with dyslipidemia (low HDL-C), long duration of diabetes, and uncontrolled glycemia revealed by
higher HbA1c.
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Background
The prevalence of type 2 diabetes (T2D) and its complica-
tions are on the rise in developing countries [1-3].
Increased urinary albumin excretion (UAE) is an indicator
of damage of the vascular endothelium, an unyielding
marker of cardiovascular disease pathologies [4,5] and
renal impairment [6], and a strong marker of developing
diabetes complications [1]. In Iran as a developing nation,
diabetes is noticeably common (7.7% of 25–64 year old
population) [8] and the association of diabetes and acute
coronary events are well underscored [9]. Nevertheless,
the prevalence and correlates of increased UAE have not
been studied in Iranian diabetic patients so far. The intent
of the present study was thus to study the prevalence of
albuminuria and its correlates in an Iranian type 2 dia-
betic population.
Methods
An uncontrolled registry single centre cross sectional
study was conducted from October 2002 to September
2003 in the outpatient diabetes clinic of Vali-Asr Hospital,
a teaching university hospital of Tehran University of
Medical sciences (Tehran, Iran). Patients with T2D visited
by two of the authors (M.N. and N.A.) were invited to par-
ticipate in this study. Patients with elevated serum creati-
nine (1.3 mg/dl for women and 1.5 mg/dl for men), overt
proteinuria revealed by dipstick, those with evidence of
non-diabetic renal disease, heart failure, systemic or local
infections, and those with FBS > 400 mg/dl were not
included. Records of patients were reviewed and the diag-
nosis of T2D was established according to the criteria of
the American Diabetes Association [10]. Health character-
istics and demographic data of patients, including age,
duration of diabetes and smoking were obtained by data
sheet review. Height, weight in light clothing, and blood
pressure (in sitting position after 10 minutes rest) were
measured. The study protocol was approved by the review
board of Endocrine Research Council and medical ethics
committee of Tehran University of Medical sciences. All
subjects gave informed consent.
Out of 435 visited eligible type 2 diabetic patients, 400
individuals participated in the biochemical examination
and completed the study with valid UAE measurements.
Twelve hour fasting blood samples of the patients were
collected within one month of the visit. The patients were
instructed to collect their urine in acid boric supplied con-
tainers from 7 pm to 7 am under standard conditions.
Glucose, creatinine, triglyceride, total cholesterol, high-
density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C), apoprotein B [apo(B)],
and lipoprotein a [Lp(a)] were determined in blood sam-
ples and urine analyses were performed. Glycated hemo-
globin (HbA1c) was determined in blood samples since
June 2003 (122 patients). HDL-C, apo(B), and triglycer-
ide were determined using immunoinhibition, immuno-
turbidometry, and Tinder enzymatic methods,
respectively. UAE was measured by latex turbidimetric
immunoassay method employing DAKO (Glostrop, Den-
mark) package.
Definition of variables
Obesity was defined as body mass index (BMI, weight
divided by square of height) equal or more than 30 kg/m2
[11]. Hypertension was defined as the use of antihyper-
tensive medication(s) or systolic blood pressure (SBP) of
≥ 140 mmHg or diastolic blood pressure (DBP) of ≥ 90
mmHg [12]. Smoking was defined as a history of regular
daily smoking equal or more than one pack-year. Subjects
with UAE > 30 mg/24 h were defined as having abnormal
UAE or albuminuria. Normo-, micro-, and macro-albu-
minuria were defined as UAE < 30 mg/24 h, between 30–
300 mg/24 h, and >300 mg/24 h. Twelve-hour overnight
UAE level was doubled as an estimate of 24 hour UAE.
Dyslipidemia was defined as LDL-C > 100 mg/dl, HDL-C
< 40 mg/dl for men and <50 mg/dl for women, triglycer-
ide > 150 mg/dl, apo (B) > 110 mg/dl, or Lp(a) > 30 mg/
dl. Glomerular filtration rate (GFR) was calculated based
on the Cockcroft-Gault formula estimated creatinine
clearance.
Statistical methods
Health characteristics of subjects with normal and abnor-
mal UAE were compared with Chi-square analysis for
qualitative data and Student's t-test for quantitative data,
wherever appropriate. A series of bivariate regression anal-
yses were used to examine the association of abnormal
albuminuria with different independent variables includ-
ing age, sex, duration of diabetes, BMI, glycated hemo-
globin, triglyceride, total cholesterol, LDL-C, HDL-C,
apo(B), and Lp(a). Mutivariate linear and binary
(increased vs. normal UAE) regression models were
designed to examine the correlates of abnormal albu-
minuria employing significant correlated variables of
bivariate regression analyses. The univariate general linear
model was applied to perform regression analysis and
analysis of variances for UAE levels – as dependent varia-
ble – by sex as fixed factor, and age, duration of diabetes,
and HDL-C as co-variables. Likewise, the univariate gen-
eral linear models were employed to examine the equality
of HDL-C among different albuminuria and sex strata
with the confounding variables as covariates including
age and duration of diabetes. A probability level of < 0.05
was considered statistically significant. Data was analyzed
using SPSS Version 13.0 for Windows (SPSS, Chicago, IL).
Results
Out of 400 (116 males and 284 females) diabetic patients,
133 individuals had microalbuminuria (33%; 95% confi-
dence intervals (CI): 28–38%), and 23 had macroalbu-
minuria (5.8%; CI: 3.5–8%). Subjects with abnormal UAE
had lower HDL-C (42.6 ± 13.5 vs.46.1 ± 16.1 mg/dl; p <Lipids in Health and Disease 2008, 7:28 http://www.lipidworld.com/content/7/1/28
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0.05), higher triglyceride (225.1 ± 139.3 vs. 199.2 ± 116.6
mg/dl; p = 0.055) and longer durations of diabetes (10.8
± 8 vs. 7.7 ± 6.8 years; p < 0.001). Age, BMI, SBP and DBP,
and serum lipids including LDL and total cholesterol,
apo(B) and Lp(a) were not different between subjects
with normal and abnormal UAE (table 1). In females, dif-
ferences of HDL-C, triglyceride, and duration of diabetes
between subjects with normal and abnormal albuminuria
were found to be significant. In males, the difference of
duration of diabetes between those with abnormal and
normal UAE was significant.
The frequency of increased UAE was significantly higher
in men than in women (51% vs. 34%, p < 0.005). Male
participants were older than females (56.9 ± 11.7 vs. 53.4
± 10.4 years, p < 0.05) but the duration of diabetes was the
same in males and females (9.5 ± 8.3 vs. 8.6 ± 7.1 years).
Women had higher mean BMI, DBP, total cholesterol,
LDL-C, HDL-C, triglyceride, apo(B), and Lp(a) compared
to men (data not shown). The mean UAE value was higher
in men compared to women (145.5 vs. 72.1 mg/day; p <
0.05); however, age adjusted UAE of men was not signifi-
cantly higher than that of women (134.4 mg/day (95%
confidence intervals: 78.6–190.2) vs. 77.8 mg/day (42.8–
112.8); p = .09); likewise, age and HDL-C adjusted UAE
values were respectively 120.1 mg/day (CI: 61.2–179) and
87.9 mg/day (CI: 51.1–124.7) in males and females (p =
0.37).
Results of regression analyses are shown in table 2. In
bivariate analyses, UAE was correlated with HDL-C (r = -
0.15; p < 0.001), duration of diabetes (r = 0.13; p < 0.05),
and HbA1c (r = -0.24, p < 0.001). UAE had no significant
correlation with age, BMI, SBP and DBP, blood glucose
level, total cholesterol, LDL-C, triglyceride, apo(B), Lp(a),
and GFR. None of the above mentioned variables was
found to have significant correlation with UAE in males.
In females, duration of diabetes (r = 0.2; p < 0.005), HDL-
C (r = 0.16; p < 0.05), Lp(a) (r = 0.14; p < 0.05), and
HbA1c (r = 0.3; p < 0.005) correlated with UAE. Two mod-
els including sex, duration of diabetes, HDL-C, and Lp(a)
with and without HbA1c were designed for multivariate
analyses of the correlates of abnormal UAE. In first model,
duration of diabetes and HDL-C levels were associated
with UAE (P < 0.005). In second multivariate regression
model, HDL-C and HbA1c were associated with UAE (P <
0.01).
Discussion
This study showed a relatively high prevalence of albu-
minuria (40%) in a population of Iranian type 2 diabetic
patients who had an average duration of diabetes of 9
years. However, men had higher mean value of UAE com-
pared to women, the age and HDL-C adjusted UAE levels
of men and women were not significantly different. Albu-
minuria was significantly associated with the duration of
diabetes in patients. HDL-C levels were lower among sub-
jects with increased UAE and UAE was higher among
those with uncontrolled glycemia (indicated by higher
HbA1c levels).
The prevalence of albuminuria in diabetic patients of this
study is in accordance with other reported cumulative
incidence of albuminuria 5 to 10 years after diagnosis of
T2D in other studies [13,14]. It has been clearly demon-
strated that cumulative incidence or prevalence of micro-
albuminuria and renal impairment is associated with a
longer duration of diabetes [15]. Despite the higher mean
level of unadjusted UAE in men as compared to women,
the difference in age and HDL-C adjusted UAE values of
males and females was not statistically significant. Such a
difference in unadjusted UAE values between men and
Table 1: Health characteristics of participants in respect to gender and urinary albumin excretion
Males (n = 116) Females (n = 284) Total
Normal UAE 
(n = 57)
Abnormal UAE
(n = 59)
Normal UAE 
(n = 187)
Abnormal UAE
(n = 97)
Normal UAE 
(n = 244)
Abnormal UAE
(n = 165)
All participants
(n = 400)
Age 56.5(12.6) 57.3(10.8) 52.8(10.4) 54.7(10.3) 53.6(11) 55.6(10.5) 54.4(10.9)
duration of diabetes(yr) 7.2(6.4) 12(9.3) † 7.8(6.9) 10.1(7.2) † 7.7(6.8) 10.8(8)† 8.9(7.4)
Systolic BP 126.9(17.1) 131.2(13.9) 132.4(21.7) 135(21.7) 131.2(20.8) 133.6(19.2) 132.1(20.2)
Diastolic BP 75.7(11.7) 79.8(9.5) 80.9(11.5) 82.2(11.9) 79.7(11.7) 81.3(11.1) 80.3(11.5)
GFR (calculated) 90.3(39.2) 89.4(33.1) 94.2(29.3) 88.3(39.4) 93.5(31.1) 88.7(37.3) 91.7(33.6)
Cholesterol 193.4(45.7) 188(60.2) 231.9(70.5) 230(63.3) 223.1(67.5) 213.9(65.2) 219.4(66.7)
HDL-C 39.9(11.7) 39.6(16.6) 48(16.8) 44.4(10.9) † 46.1(16.1) 42.6(13.5) † 44.7(15.2)
LDL-C 120.1(35.7) 116.5(43.5) 141.3(47.6) 135.8(46.1) † 136.2(45.9) 128.1(45.9) 133(46)
Triglycerides 166.1(75.9) 180.9(106.5) 209.2(124.8) 252.6(150.4) 199.2(116.6) 225.1(139.3) 209.5(126.6)
APOB 101.9(23.2) 97.6(29.8) 114.9(32) 118.5(29.7) 111.9(30.7) 110.4(31.4) 111.3(30.9)
Lp(a) 45.6(37.8) 38.3(37.2) 48.5(37.3) 59.8(52.4) 47.8(37.4) 51.4(48.1) 49.2(41.9)
FPG 222.5(81.1) 191.9(70.6) 194(70.4) 214.9(94.8) 199.7(73.3) 206.5(87.1) 202.3(78.8)
HbA1c 7.8(2.1) 9.5(2.5) 9.2(2.8) 10(3.6) 8.9(2.7) 9.8(3.2) 9.3(3)
Data are mean (standard deviation); † indicates p < 0.05; BP: blood pressure; FPG: fasting plasma glucose; GFR: glomerular filtration rateLipids in Health and Disease 2008, 7:28 http://www.lipidworld.com/content/7/1/28
Page 4 of 5
(page number not for citation purposes)
women could be simply attributed to different prevalence
of other cardiovascular risk factors between the two gen-
ders. This result support the idea that men and women
with similar levels of cardiovascular risk factors may be
expected to have similar risk of albuminuria. This has
been shown by some prospective studies reporting that
male sex does not increase the risk of progression to albu-
minuria, independent of the effect of other predictors [16-
21], but is in contrast with the findings of PREVEND study
which concluded that gender differences existed in the
association between cardiovascular risk factors and UAE
[22].
Molich et al has exhibited the association of lower HDL
level and UAE in patients with long standing type 1 diabe-
tes [23]. This study confirms such an association in sub-
jects with type 2 diabetes. Increased UAE in patients with
dyslipidemia may be secondary to dyslipidemia associ-
ated endovascular damage [24-27]. In this regard, there is
some evidence that lipid reduction by antilipemic agents
might decrease proteinuria in diabetic patients [28,29];
however, presence of direct causal correlation between
dyslipidemia and diabetic renal damage is still a subject of
controversy [30,31].
This study suffers from some limitations. Firstly, the UAE
was measured once which may obscure conclusions on
persistent albuminuria and the risk of progression to
incipient or overt diabetic renal damage due to fluctua-
tions in UAE in the course of disease. This is however a
limitation of any cross-sectional study in this field. Sec-
ondly, we did not collect certain important variables such
as diet, anemia, and drug history which might differ sub-
stantially between genders and may impact on the results.
However, ignored confounding factors are more likely to
cause false positive correlations rather than false negative
results. Furthermore, we did not collect the history of car-
diovascular diseases in our patients. Thirdly, HbA1c was
integrated into our study for the final few month of the
study period.
Table 2: Correlates of increased urinary albumin excretion
Binary logistic regression Linear Regression
EXP(B) 95% CI for EX9B) sig beta sig
Bivariate Analyses
Age 1.018 (0.997–1.038) 0.09 0.087 0.104
Duration of diabetes 1.058 (1.026–1.091) 0 0.128 0.018
BMI 0.984 (0.942–1.027) 0.449 -0.009 0.865
SBP 1.006 (0.995–1.017) 0.286 0.094 0.082
DBP 1.012 (0.993–1.032) 0.209 0.075 0.163
Cholesterol 0.998 (0.995–1.001) 0.197 -0.066 0.207
Triglycerides 1.002 (1–1.003) 0.058 -0.012 0.819
HDL-C 0.984 (0.97–0.998) 0.03 -0.148 0.005
APOB 0.998 (0.992–1.005) 0.641 -0.032 0.542
LDL-C 0.996 (0.991–1.001) 0.115 -0.033 0.548
Lp(a) 1.002 (0.997–1.007) 0.423 0.063 0.233
HbA1C 1.106 (0.975–1.254) 0.118 0.239 0.008
GFR 1.003 (0.998–1.009) 0.229 -0.119 0.062
Sex (referent: male) 0.501 (0.323–0.777) 0.002 -0.124 0.013
Smoking 2.602 (1.304–5.194) 0.007 0.03 0.605
Multivariate Analyses Model 1
Sex 0.618 (0.367–1.041) 0.07 -0.057 0.31
Duration of diabetes 1.065 (1.03–1.101) 0 0.156 0.005
HDL-C 0.978 (0.962–0.995) 0.012 -0.176 0.002
Model 2
Sex 0.526 (0.193–1.433) .209 -0.105 0.261
Duration of diabetes 1.060 (1.005–1.119) .032 0.132 0.150
HDL-C 0.961 (0.929–0.994) .021 -0.255 0.007
HbA1c 1.200 (1.028–1.4) .021 0.261 0.005
Data are Exp B (confidence intervals), Beta Standardized Coefficients, and p values (sig).
BMI:body mass index;SBP: systolic blood pressure; DBP: diastolic blood pressure; GFR: glomerular filtration rate
Predictors of Model 1: HDL-C, duration of diabetes (yrs), and sex; Predictors of Model 2: HbA1C, HDL-C, duration of diabetes(yr), and sexLipids in Health and Disease 2008, 7:28 http://www.lipidworld.com/content/7/1/28
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Conclusion
We conclude that HDL-C and duration of diabetes are
associated with increased UAE. Abnormal UAE is more
frequent in men but this higher frequency may be
explained by higher other cardiovascular risk factors in
male gender.
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